Does 4-factor prothrombin concentrate (4F-PCC) reduce 24 h blood product consumption in trauma patients at risk of massive transfusion?

被引：0
|
作者：
Newton, Hailey [1 ]
Drew, Doran [1 ,2 ]
Perry, Jeffrey J. [1 ,3 ]
机构：
[1] Univ Ottawa, Ottawa Hosp, Dept Emergency Med, Ottawa, ON, Canada
[2] Univ Ottawa, Dept Surg, Div Trauma, Ottawa, ON, Canada
[3] Ottawa Hosp Res Inst, Ottawa, ON, Canada
来源：
CANADIAN JOURNAL OF EMERGENCY MEDICINE | 2023年 / 25卷 / 12期
关键词：
D O I：
10.1007/s43678-023-00587-y
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：946 / 948
页数：3
相关论文
共 37 条
  • [21] HEALTHCARE RESOURCE UTILIZATION FOR INTRACRANIAL HEMORRHAGE TREATED WITH FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (4F-PCC) IN A US HOSPITAL DATABASE
    Mahan, C.
    Wassel, C.
    Gayle, J.
    Dreyfus, J.
    Mcneil-Posey, K.
    Lovelace, B.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 531 - 531
  • [22] Four-Factor Prothrombin Complex Concentrate (4F-PCC) Effectively Reverses Rivaroxaban Induced Bleeding in a Rabbit Model of Acute Bleeding
    Herzog, Eva
    Mueller-Cohrs, Jochen
    Kaspereit, Franz
    Krege, Wilfried
    Niebl, Peter
    Doerr, Baerbel
    Schulte, Stefan
    Dickneite, Gerhard
    BLOOD, 2014, 124 (21)
  • [23] Comparison of 3-Factor Versus 4-Factor Prothrombin Complex Concentrate With Regard to Warfarin Reversal, Blood Product Use, and Costs
    DeAngelo, Jessica
    Jarrell, Daniel
    Cosgrove, Richard
    Camamo, James
    Edwards, Christopher
    Patanwala, Asad E.
    AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (03) : E326 - E332
  • [24] 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE ADMINISTRATION DOES NOT ALTER THE AMOUNT OF FRESH FROZEN PLASMA TRANSFUSED IN A 24-HOUR PERIOD
    Pokrandt, Paul
    Roberts, Sammie
    Engoren, Milo
    Jewell, Elizabeth S.
    Berg, Mary
    Maile, Michael
    ANESTHESIA AND ANALGESIA, 2019, 128 : 121 - 122
  • [25] Risk Profile of Administration of 3-and 4-factor Prothrombin Complex Concentrate in Adult Anticoagulated Trauma Patients: A Systematic Review and Meta-Analysis
    Newman, Charles
    Melhuish, Jake
    Spence-Jones, Helen
    Shepherd, Joanna
    BRITISH JOURNAL OF SURGERY, 2024, 111
  • [26] Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages
    Barra, Megan E.
    Das, Alvin S.
    Hayes, Bryan D.
    Rosenthal, Eric S.
    Rosovsky, Rachel P.
    Fuh, Lanting
    Patel, Aman B.
    Goldstein, Joshua N.
    Roberts, Russel J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (07) : 1637 - 1647
  • [27] Comparison of blood product use and costs with use of 3-factor versus 4-factor prothrombin complex concentrate for off-label indications
    DeAngelo, Jessica
    Jarrell, Daniel H.
    Cosgrove, Richard
    Camamo, James
    Edwards, Christopher J.
    Patanwala, Asad E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (15) : 1103 - 1109
  • [28] ENDOGENOUS THROMBIN POTENTIAL FOLLOWING HEMOSTATIC THERAPY WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE: A 7-DAY OBSERVATIONAL STUDY OF TRAUMA PATIENTS
    Papakitsos, G.
    Kapsali, A.
    Papakitsou, T.
    HAEMATOLOGICA, 2015, 100 : 139 - 139
  • [29] Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients
    Herbert Schöchl
    Wolfgang Voelckel
    Marc Maegele
    Lukas Kirchmair
    Christoph J Schlimp
    Critical Care, 18
  • [30] Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients
    Schoechl, Herbert
    Voelckel, Wolfgang
    Maegele, Marc
    Kirchmair, Lukas
    Schlimp, Christoph J.
    CRITICAL CARE, 2014, 18 (04):
1234